TVRD — Tvardi Therapeutics Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Tvardi Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 23 | 41.9 | 21 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | 34.6 | 14.8 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 112 | 129 | 142 | 28.1 | 26.7 |
| Operating Profit | -89.1 | -87.5 | -121 | -28.1 | -26.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -88.4 | -85.5 | -119 | -29.4 | -18.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -88.4 | -85.5 | -119 | -29.4 | -18.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -88.4 | -85.5 | -119 | -29.4 | -18.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -88.4 | -85.5 | -119 | -29.4 | -18.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -62.8 | -57.4 | -78.8 | -11.4 | -2.46 |